Vaccination Against Influenza Pre-discharge in Heart Failure
NCT ID: NCT06725927
Last Updated: 2025-07-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE4
200 participants
INTERVENTIONAL
2024-12-31
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Coordinated Vaccination Against RSV and Influenza in Patients With Chronic Heart Failure and Its Impact on Prognosis.
NCT06259487
Flu Vaccination in Congestive Heart Failure
NCT00664339
VAccination to Improve Clinical outComes in Heart Failure Trial: a Feasibility Study (VACC-HeFT)
NCT02268500
Impact of a Letter Encouraging Pneumococcal Vaccination on the 1-year Vaccination Rate in Heart Failure Patients With a Primary Care Physician
NCT06360315
InFLUenza and the HEART An Investigation Into the Acute and Lasting Cardiac Effects of Influenza Infection
NCT05084846
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Influenza vaccination
Vaccination pre-discharge in patients stabilized after heart failure exacerbation
Influenza vaccination
Influenza vaccination pre-discharge in patients hospitalized due to heart failure exacerbation
Standard of care
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Influenza vaccination
Influenza vaccination pre-discharge in patients hospitalized due to heart failure exacerbation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* hospitalization (unplanned) due to exacerbation (decompensation) of heart failure
* planned discharge within the next 48 hours due to completion of hospital treatment
* no current (2024/25 season) influenza vaccination.
Exclusion Criteria
* hypersensitivity to any of the components of the vaccine planned to be administered
* discharge to another hospital for continued treatment or discharge to a nursing home
* antibiotic therapy among the drugs recommended for taking after hospitalization.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wroclaw Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Michał Tkaczyszyn, MD
Dr
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jan Biegus, Professor
Role: STUDY_CHAIR
Wroclaw Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jan Mikulicz Radecki University Hospital in Wroclaw
Wroclaw, Lower Silesian Voivodeship, Poland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KB 659/2024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.